Col10A1 is a Potential Immunotherapy Biomarker Associated With Immune Infiltration and Deficient Mismatch Repair in Colon Cancer

References

• Sung H , FerlayJ , SiegelRLet.al Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Siegel RL , MillerKD , WagleNS , JemalA. Cancer statistics, 2023. CA Cancer J. Clin.73(1), 17–48 (2023).
   PubMed Web of Science ®Google Scholar
• Morgan E , ArnoldM , GiniAet.al Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut72(2), 338–344 (2023).
   PubMed Web of Science ®Google Scholar
• Ganesh K , StadlerZK , CercekAet.al Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol.16(6), 361–375 (2019).
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr , LeDT. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med.373(20), 1979 (2015).
   PubMed Web of Science ®Google Scholar
• Smith KM , DesaiJ. Nivolumab for the treatment of colorectal cancer. Expert Rev. Anticancer. Ther.18(7), 611–618 (2018).
   PubMed Web of Science ®Google Scholar
• Romero D . New first-line therapy for dMMR/MSI-H CRC. Nat. Rev. Clin. Oncol.18(2), 63 (2021).
   PubMed Web of Science ®Google Scholar
• Overman MJ , McdermottR , LeachJLet.al Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol.18(9), 1182–1191 (2017).
   PubMed Web of Science ®Google Scholar
• Overman MJ , LonardiS , WongKYMet.al Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol.36(8), 773–779 (2018).
   PubMed Web of Science ®Google Scholar
• Schrock AB , OuyangC , SandhuJet.al Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann. Oncol.30(7), 1096–1103 (2019).
   PubMed Web of Science ®Google Scholar
• Galon J , CostesA , Sanchez-CaboFet.al Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science313(5795), 1960–1964 (2006).
   PubMed Web of Science ®Google Scholar
• Le DT , DurhamJN , SmithKNet.al Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science357(6349), 409–413 (2017).
   PubMed Web of Science ®Google Scholar
• Kielty CM , KwanAP , HolmesDF , SchorSL , GrantME. Type X collagen, a product of hypertrophic chondrocytes. Biochem. J.227(2), 545–554 (1985).
   PubMed Web of Science ®Google Scholar
• Lu P , WeaverVM , WerbZ. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol.196(4), 395–406 (2012).
   PubMed Web of Science ®Google Scholar
• Chen S , WeiY , LiuHet.al Analysis of collagen type X alpha 1 (COL10A1) expression and prognostic significance in gastric cancer based on bioinformatics. Bioengineered12(1), 127–137 (2021).
   PubMed Web of Science ®Google Scholar
• Zhou W , LiY , GuDet.al High expression COL10A1 promotes breast cancer progression and predicts poor prognosis. Heliyon8(10), e11083 (2022).
   PubMed Web of Science ®Google Scholar
• Liang Y , XiaW , ZhangTet.al Upregulated collagen COL10A1 remodels the extracellular matrix and promotes malignant progression in lung adenocarcinoma. Front. Oncol.10, 573534 (2020).
   PubMed Web of Science ®Google Scholar
• Huang H , LiT , YeGet.al High expression of COL10A1 is associated with poor prognosis in colorectal cancer. Onco Targets Ther.11, 1571–1581 (2018).
   PubMed Web of Science ®Google Scholar
• Kahlert UD , ShiW , StreckerMet.al COL10A1 allows stratification of invasiveness of colon cancer and associates to extracellular matrix and immune cell enrichment in the tumor parenchyma. Front. Oncol.12, 1007514 (2022).
   PubMed Web of Science ®Google Scholar
• Bonneville R , KrookMA , KauttoEAet.al Landscape of microsatellite instability across 39 cancer types. JCO Precis. Oncol.2017, doi: 10.1200/PO.17.00073 (2017).
   PubMed Web of Science ®Google Scholar
• Bindea G , MlecnikB , TosoliniMet.al Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity39(4), 782–795 (2013).
   PubMed Web of Science ®Google Scholar
• Charoentong P , FinotelloF , AngelovaMet.al Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep.18(1), 248–262 (2017).
   PubMed Web of Science ®Google Scholar
• Xu L , DengC , PangBet.al TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res.78(23), 6575–6580 (2018).
   PubMed Web of Science ®Google Scholar
• Yoshihara K , ShahmoradgoliM , MartínezEet.al Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun.4, 2612 (2013).
   PubMed Web of Science ®Google Scholar
• Wang X , BaiY , ZhangFet.al Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: a comprehensive study based on bioinformatics and clinical analysis validation. Front. Immunol.14, 955949 (2023).
   PubMed Web of Science ®Google Scholar
• Mao X , XuJ , WangWet.al Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol. Cancer20(1), 131 (2021).
   PubMed Web of Science ®Google Scholar
• Qian BZ , PollardJW. Macrophage diversity enhances tumor progression and metastasis. Cell141(1), 39–51 (2010).
   PubMed Web of Science ®Google Scholar
• Biswas SK , AllavenaP , MantovaniA. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin. Immunopathol.35(5), 585–600 (2013).
   PubMed Web of Science ®Google Scholar
• Hu W , LiX , ZhangC , YangY , JiangJ , WuC. Tumor-associated macrophages in cancers. Clin. Transl. Oncol.18(3), 251–258 (2016).
   PubMed Web of Science ®Google Scholar
• Laoui D , Van OvermeireE , MovahediKet.al Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology216(11), 1192–1202 (2011).
   PubMed Web of Science ®Google Scholar
• Schouppe E , DeBaetselier P , Van GinderachterJA , SarukhanA. Instruction of myeloid cells by the tumor microenvironment: open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. Oncoimmunology1(7), 1135–1145 (2012).
   PubMed Web of Science ®Google Scholar
• Mclean MH , MurrayGI , StewartKNet.al The inflammatory microenvironment in colorectal neoplasia. PLOS ONE6(1), e15366 (2011).
   PubMed Web of Science ®Google Scholar
• Chen K , LiuQ , TsangLLet.al Human MSCs promotes colorectal cancer epithelial–mesenchymal transition and progression via CCL5/β-catenin/Slug pathway. Cell Death Dis.8(5), e2819 (2017).
   PubMedGoogle Scholar
• Chun E , LavoieS , MichaudMet.al CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep.12(2), 244–257 (2015).
   PubMed Web of Science ®Google Scholar
• Sasaki S , BabaT , ShinagawaK , MatsushimaK , MukaidaN. Crucial involvement of the CCL3–CCR5 axis-mediated fibroblast accumulation in colitis-associated carcinogenesis in mice. Int. J. Cancer135(6), 1297–1306 (2014).
   PubMed Web of Science ®Google Scholar
• Fisher RC , BellamkondaK , AlexMolina Let.al Disrupting inflammation-associated CXCL8–CXCR1 signaling inhibits tumorigenicity initiated by sporadic- and colitis-colon cancer stem cells. Neoplasia21(3), 269–281 (2019).
   PubMed Web of Science ®Google Scholar
• Chen DS , MellmanI. Oncology meets immunology: the cancer-immunity cycle. Immunity39(1), 1–10 (2013).
   PubMed Web of Science ®Google Scholar
• Liu Q , YangC , WangSet.al Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression. Cell Commun. Signal.18(1), 51 (2020).
   PubMed Web of Science ®Google Scholar
• Wei C , YangC , WangSet.al Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol. Cancer18(1), 64 (2019).
   PubMedGoogle Scholar
• Cristescu R , MoggR , AyersMet.al Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science362(6411), eaar3593 (2018).
   PubMed Web of Science ®Google Scholar
• Sharma P , SiddiquiBA , AnandhanSet.al The next decade of immune checkpoint therapy. Cancer Discov.11(4), 838–857 (2021).
   PubMed Web of Science ®Google Scholar
• Lenz HJ , Van CutsemE , LuisaLimon Met.al First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. J. Clin. Oncol.40(2), 161–170 (2022).
   PubMed Web of Science ®Google Scholar
• Cohen R , BennounaJ , MeurisseAet.al RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. J. Immunother. Cancer8(2), e001499 (2020).
   PubMed Web of Science ®Google Scholar
• Le DT , UramJN , WangHet.al PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med.372(26), 2509–2520 (2015).
   PubMed Web of Science ®Google Scholar
• Le DT , KimTW , Van CutsemEet.al Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J. Clin. Oncol.38(1), 11–19 (2020).
   PubMed Web of Science ®Google Scholar
• Dolcetti R , VielA , DoglioniCet.al High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am. J. Pathol.154(6), 1805–1813 (1999).
   PubMed Web of Science ®Google Scholar
• Smyrk TC , WatsonP , KaulK , LynchHT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer91(12), 2417–2422 (2001).
   PubMed Web of Science ®Google Scholar
• Nagorsen D , VoigtS , BergE , SteinH , ThielE , LoddenkemperC. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J. Transl. Med.5, 62 (2007).
   PubMed Web of Science ®Google Scholar